据我们的了解，目前只有少数研究对替莫唑芬（TMX）耐药个体的生物能学进行了调查，并报告了线粒体活性和代谢特征的改变。TMX耐药的主要原因被坚定地认为是代谢变化。代谢变异和低氧也被双向关联起来。低氧水平的增加与早期复发和增殖呈正相关，并对乳腺癌（BC）患者的治疗产生负面影响。低氧、癌变和患者死亡之间存在相关性，导致更具侵袭性的特征、转移的几率增加和TMX耐药。因此，我们希望调查代谢/低氧轴上长链非编码RNA（LncRNA）Taurine up-regulated 1（TUG-1）、微小RNA-186-5p（miR-186）、Sirtuin-3（SIRT3）、过氧化物酶增殖活化受体α（PPAR-α）和低氧诱导因子-1（HIF-1）在乳腺癌（BC）患者中发展TMX耐药的潜在作用，并将其与肿瘤进展进行相关性研究。有趣的是，这将是首次探索乳腺癌中该轴的表观遗传调控。© 2023. 作者。

Only a few investigations, to our knowledge, have examined the bioenergetics of Tamoxifen (TMX) resistant individuals and reported altered mitochondrial activity and metabolic profile. The primary cause of TMX resistance is firmly suggested to be metabolic changes. Metabolic variations and hypoxia have also been linked in a bidirectional manner. Increased hypoxic levels correlate with early recurrence and proliferation and have a negative therapeutic impact on breast cancer (BC) patients. Hypoxia, carcinogenesis, and patient death are all correlated, resulting in more aggressive traits, a higher chance of metastasis, and TMX resistance. Consequently, we sought to investigate the possible role of the metabolic/hypoxial axis Long non-coding RNA (LncRNA) Taurine up-regulated 1 (TUG-1), Micro-RNA 186-5p (miR-186), Sirtuin-3 (SIRT3), Peroxisome Proliferator Activator Receptor alpha (PPAR-α), and Hypoxia-Inducible Factor-1 (HIF-1) in the development of TMX resistance in BC patients and to correlate this axis with tumor progression. Interestingly, this will be the first time to explore epigenetic regulation of this axis in BC.© 2023. The Author(s).